REYON Pharmaceutical Co., Ltd. (102460.KS)
KRW 13020.0
(-2.18%)
KRW 13020.0
(-2.18%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 195.38 KRW | -52.86% |
| 2022 | 414.51 KRW | 35.71% |
| 2021 | 305.44 KRW | 35.3% |
| 2020 | 225.75 KRW | -21.52% |
| 2019 | 287.64 KRW | 262.22% |
| 2018 | 79.41 KRW | -89.45% |
| 2017 | 752.94 KRW | 56.49% |
| 2016 | 481.15 KRW | -27.42% |
| 2015 | 662.90 KRW | -2.22% |
| 2014 | 677.98 KRW | 2.74% |
| 2013 | 659.88 KRW | -33.56% |
| 2012 | 993.21 KRW | -14.09% |
| 2011 | 1156.11 KRW | -3.22% |
| 2010 | 1194.57 KRW | 19.01% |
| 2009 | 1003.77 KRW | 81.09% |
| 2008 | 554.30 KRW | -95.25% |
| 2007 | 11.67 Thousand KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | 17.78 KRW | 132.96% |
| 2024 Q2 | 35.97 KRW | 102.31% |
| 2023 Q4 | -53.94 KRW | -880.73% |
| 2023 Q2 | 149.13 KRW | 33.13% |
| 2023 Q3 | -5.50 KRW | -103.69% |
| 2023 FY | - KRW | -52.86% |
| 2023 Q1 | 112.02 KRW | -48.79% |
| 2022 Q4 | 218.75 KRW | 86.0% |
| 2022 Q3 | 117.61 KRW | 605.2% |
| 2022 Q1 | 88.88 KRW | 10.1% |
| 2022 FY | - KRW | 35.71% |
| 2022 Q2 | -23.28 KRW | -126.19% |
| 2021 Q3 | 1.00 KRW | -99.42% |
| 2021 Q1 | 57.00 KRW | -39.06% |
| 2021 FY | - KRW | 35.3% |
| 2021 Q2 | 172.00 KRW | 201.75% |
| 2021 Q4 | 80.73 KRW | 7973.0% |
| 2020 Q3 | 49.02 KRW | -35.9% |
| 2020 Q2 | 76.47 KRW | 7703.06% |
| 2020 Q1 | 0.98 KRW | -96.32% |
| 2020 FY | - KRW | -21.52% |
| 2020 Q4 | 93.53 KRW | 90.8% |
| 2019 Q2 | 81.37 KRW | -50.89% |
| 2019 Q4 | 26.64 KRW | -66.03% |
| 2019 FY | - KRW | 262.22% |
| 2019 Q1 | 165.69 KRW | 168.42% |
| 2019 Q3 | 78.43 KRW | -3.61% |
| 2018 Q3 | 27.45 KRW | -88.48% |
| 2018 FY | - KRW | -89.45% |
| 2018 Q4 | -242.18 KRW | -982.26% |
| 2018 Q2 | 238.24 KRW | 395.92% |
| 2018 Q1 | 48.04 KRW | -33.18% |
| 2017 FY | - KRW | 56.49% |
| 2017 Q4 | 71.89 KRW | -75.3% |
| 2017 Q3 | 291.10 KRW | 86.47% |
| 2017 Q2 | 156.11 KRW | -25.27% |
| 2017 Q1 | 208.90 KRW | 81.24% |
| 2016 Q3 | 133.48 KRW | -1.67% |
| 2016 FY | - KRW | -27.42% |
| 2016 Q4 | 115.26 KRW | -13.65% |
| 2016 Q2 | 135.75 KRW | -43.75% |
| 2016 Q1 | 241.33 KRW | 942.46% |
| 2015 Q3 | 222.47 KRW | 17.06% |
| 2015 Q4 | 23.15 KRW | -89.59% |
| 2015 Q2 | 190.05 KRW | -16.28% |
| 2015 Q1 | 227.00 KRW | 44.25% |
| 2015 FY | - KRW | -2.22% |
| 2014 Q4 | 157.37 KRW | -16.86% |
| 2014 Q2 | 157.62 KRW | -8.73% |
| 2014 Q1 | 172.70 KRW | -15.85% |
| 2014 FY | - KRW | 2.74% |
| 2014 Q3 | 189.29 KRW | 20.09% |
| 2013 Q1 | 141.78 KRW | -47.24% |
| 2013 Q2 | 95.02 KRW | -32.98% |
| 2013 Q4 | 205.23 KRW | -6.16% |
| 2013 Q3 | 218.70 KRW | 130.16% |
| 2013 FY | - KRW | -33.56% |
| 2012 FY | - KRW | -14.09% |
| 2012 Q4 | 268.72 KRW | -3.44% |
| 2012 Q3 | 278.28 KRW | 5.73% |
| 2012 Q2 | 263.20 KRW | 43.62% |
| 2012 Q1 | 183.26 KRW | -32.48% |
| 2011 Q2 | 260.94 KRW | -32.81% |
| 2011 Q1 | 388.39 KRW | 23.66% |
| 2011 Q3 | 236.05 KRW | -9.54% |
| 2011 Q4 | 271.41 KRW | 14.98% |
| 2011 FY | - KRW | -3.22% |
| 2010 Q3 | 350.68 KRW | 19.54% |
| 2010 FY | - KRW | 19.01% |
| 2010 Q2 | 293.36 KRW | 0.0% |
| 2010 Q4 | 314.08 KRW | -10.44% |
| 2009 FY | - KRW | 81.09% |
| 2008 FY | - KRW | -95.25% |
| 2007 FY | - KRW | 0.0% |